scholarly journals Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria

2008 ◽  
Vol 47 (5) ◽  
pp. 674-683 ◽  
Author(s):  
Brahm H. Segal ◽  
Raoul Herbrecht ◽  
David A. Stevens ◽  
Luis Ostrosky‐Zeichner ◽  
Jack Sobel ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Fungal Diseases ◽  
Study Group ◽  
European Organization ◽  
Invasive Fungal Diseases

scholarly journals Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system

2019 ◽  
Vol 58 (4) ◽  
pp. 417-424 ◽  
Author(s):  
Stefan Schwartz ◽  
Oliver A Cornely ◽  
Kamal Hamed ◽  
Francisco M Marty ◽  
Johan Maertens ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Clinical Trials ◽  
Nervous System ◽  
Fungal Pathogens ◽  
Hematologic Malignancies ◽  
Fungal Diseases ◽  
Phase Iii ◽  
Clinical Activity ◽  
Invasive Fungal Diseases ◽  
Cryptococcus Species

Abstract The incidence of invasive fungal diseases (IFDs) with central nervous system (CNS) involvement is increasing due to the rising numbers of immunocompromised individuals, such as patients receiving chemotherapy, transplantation procedures, or immune-modulating therapies. CNS IFDs cause significant morbidity and mortality, and treatments are complicated by difficulties in identifying fungal pathogens and delivering antifungal agents to the CNS. Isavuconazole is a novel triazole with broad-spectrum activity that has shown good blood–brain barrier penetration in animal models. We present a retrospective analysis of isavuconazole in the treatment of patients with CNS IFDs and who either participated in the phase III VITAL or SECURE clinical trials, or were included in a named-patient program. A total of 36 patients were identified, including 27 patients from the clinical trials. Of these patients, 47.2% had hematologic malignancies, while 13.9% had no identifiable underlying conditions. Mucorales, Aspergillus species, and Cryptococcus species accounted for 30.6%, 22.2%, and 13.9% of infections, respectively. The overall survival rate was 80.6% at day 42 and 69.4% at day 84, and at the end of treatment, a complete or partial clinical response was achieved in 58.3% of patients. Isavuconazole exhibited clinical activity in a variety of CNS IFDs.

scholarly journals Prospective Evaluation of Serum β-Glucan Testing in Patients With Probable or Proven Fungal Diseases

2016 ◽  
Vol 3 (3) ◽  
Author(s):  
Cécile Angebault ◽  
Fanny Lanternier ◽  
Frédéric Dalle ◽  
Cécile Schrimpf ◽  
Anne-Laure Roupie ◽  
...  
Keyword(s):  
Clinical Utility ◽  
Clinical Suspicion ◽  
Fungal Diseases ◽  
Prospective Evaluation ◽  
Invasive Fungal Diseases ◽  
Undetectable Serum ◽  
Antifungal Use ◽  
Kinetics Of ◽  
Rule Out

Abstract Background.  Early diagnosis and treatment are crucial in invasive fungal diseases (IFD). Serum (1-3)-β-d-glucan (BG) is believed to be an early IFD marker, but its diagnostic performance has been ambiguous, with insufficient data regarding sensitivity at the time of IFD diagnosis (TOD) and according to outcome. Whether its clinical utility is equivalent for all types of IFD remains unknown. Methods.  We included 143 patients with proven or probable IFD (49 invasive candidiasis, 45 invasive aspergillosis [IA], and 49 rare IFD) and analyzed serum BG (Fungitell) at TOD and during treatment. Results.  (1-3)-β-d-glucan was undetectable at TOD in 36% and 48% of patients with candidemia and IA, respectively; there was no correlation between negative BG results at TOD and patients' characteristics, localization of infection, or prior antifungal use. Nevertheless, patients with candidemia due to Candida albicans were more likely to test positive for BG at TOD (odds ratio = 25.4, P = .01) than patients infected with other Candida species. In 70% of the patients with a follow-up, BG negativation occurred in >1 month for candidemia and >3 months for IA. A slower BG decrease in patients with candidemia was associated with deep-seated localizations (P = .04). Thirty-nine percent of patients with rare IFD had undetectable BG at TOD; nonetheless, all patients with chronic subcutaneous IFD tested positive at TOD. Conclusions.  Undetectable serum BG does not rule out an early IFD, when the clinical suspicion is high. After IFD diagnostic, kinetics of serum BG are difficult to relate to clinical outcome.

scholarly journals Use of Multimodality Imaging in Diagnosing Invasive Fungal Diseases of the Heart

2017 ◽  
Vol 10 (6) ◽  
Author(s):  
Ersilia M. DeFilippis ◽  
Sarah Cuddy ◽  
Carolyn Glass ◽  
Sarv Priya ◽  
Ayaz Aghayev ◽  
...  
Keyword(s):  
Multimodality Imaging ◽  
Fungal Diseases ◽  
Invasive Fungal Diseases

Review of the clinical trials activity of the soft tissue and bone sarcoma group of the european organization for research and treatment of cancer

1988 ◽  
Vol 4 (1) ◽  
pp. 45-52 ◽  
Author(s):  
Vivien H. C. Bramwell ◽  
A. Santoro ◽  
J. Rouesse ◽  
H. Mouridsen ◽  
W. Steward ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Soft Tissue ◽  
Bone Sarcoma ◽  
European Organization
Sign in / Sign up

Export Citation Format

Share Document